

National Institute for Public Health and the Environment Ministry of Health, Welfare and Sport

Development of a risk assessment strategy within the GUIDEnano project

Dr. Susan Wijnhoven RIVM

Sustainable Nanotechnology Conference 2015

Development of a risk assessment strategy within the GUIDEnano project | March 10, 2015



Project Consortium

Universities & Research Centers



























Rijksinstituut voor Volksgezondheid en Milieu Ministerie van Volksgezondheid, Welzijn en Sport









Industry































Main Goal

Develop innovative methodologies to <u>evaluate</u> and <u>manage</u> human and environmental health risks of NM-enabled products, considering the whole product life cycle




Interactive digital Guidance Tool






Target and scope

THE TARGET NM-enabled product Life Cycle



SCOPE OF THE GUIDANCE




No further action required: NM-enabled product considered safe







Organization in WPs










Project Timeline








GUIDE

The Tool



Release to relevant environmental / human compartments

Environmental fate modelling


Exposure levels and NM form in relevant environmental / human compartments

WoE / Prioritization algorithm –

Hazard endpoints values

Read-across Relevance / Quality score


Toxicity studies available to the user







Risk assessment





Risk assessment


- Risk assessment decision flow:
 - Divided in 4 main elements
 - Input and information requirements (exposure and hazard assessment)
 - Risk assessment (calculation of risk and classification into 3 categories)
 - Recommendation for follow-up actions (reduction of uncertainty, risk mitigation)
 - Output report







Risk assessment



Information requirements Risk Assessment 'Risk characterisation ratio' (RCR): exposure Assessment WP 6 Assessment WP 3,4,5

Exposure:

- relevant exposure routes/ duration
- model output, exposure libraries, direct measurement data
- Hazard:
 - relevant endpoints with (if possible) quantitative exposure estimate with uncertainty








Hazard endpoints

 Identification of human hazard endpoints to be addressed for each exposure scenario

route	duration	endpoints to be evaluated	Endpoints	Quant	itativ
inhalation	single	1246 7	1	Invitation / commonica	1
inhalation	single	1,3,4,6, 7	2	Irritation/corrosion	1
dermal	repeated	1,2,3,5,6,7,8	3	sensitisation	
uermai	single	1,3,4,6, 7	4	absorption/accumulation/elimination acute toxicity	\ \ \
oral	repeated	1,2,3,5,6,7,8 1,3,4,6,7	5	repeated dose toxicity	Y
Orai	repeated	1,2,3,5,6,7,8	6	mutagenicity	N
	repeateu	1,2,3,3,0,7,0	7	carcinogenicity	١
			8	reproductive and developmental toxicity	V






Exposure **YES** NO Low Medium High Low Medium High Hazard uncertaint Uncertaint uncertaint uncertaint Uncertaint uncertaint Low Risk No Risk uncertaint Medium **YES** No Risk Uncertaint High No Risk uncertaint Low uncertaint No Risk No Risk No Risk No Risk No Risk No Risk Medium NO No Risk Uncertaint High No Risk uncertaint

Risk assessment qualitative endpoints


Yes/No answer with uncertainty value



Uncertainty	Ratio Y/N	
Low	70-90 / 10-30	
Medium	50-70 / 30-50	
High	50/50	







Risk assessment quantitative endpoints


Exposure = certain amount per time in mass/ time or surface area/ time or number of particles/ time


Hazard = lowest exposure level at which an adverse event can be expected ('DNEL', default, PNEC)





What risk is "acceptable"?





Risk assessment quantitative endpoints

Change from acceptable to "probability of risk"

Defaults:

Acceptable risk, low probability of risk : <5% probability on a ratio of >1. Possible risk, medium probability of risk: 5-75% probability on a ratio of >1. Unacceptable risk, high probability of risk: >75% probability on a ratio of >1








Follow up actions

Possible risk: reduction of risk or reduction of uncertainty








Follow up actions

Unacceptable risk: reduction of risk









Future work: risk assessment

- Continue with tool development
- Discuss and review definition of (acceptable) risk
- Further development of uncertainty/ sensitivity analysis
- Definition of content of output report
- Stakeholder analysis of tool
- Validation with case studies





Acknowlegdements

- GUIDEnano project consortium
 - All partners
 - Gemma Janer (LEITAT)
 - Socorro Vazquez (LEITAT)
 - Margriet Park (RIVM)
 - Ralph Vanhauten (TW)
 - Lion Traas (TW)

— WP7

- Petra van Kesteren (RIVM)
- Maria Luisa Cruz- Fernandez (INIA)
- Derk Brouwer (TNO)
- Thies Oosterwijk (TNO)
- Joost Westerhout (TNO)
- Manoj Vaghela (Pinsent Masons)



GUIDE





What is uncertainty?


Measured data can be summarized with an average value and standard deviation. This is the *variance* in the data.


Extrapolation of the data (e.g. from one scenario to the next, or from animals to humans) will introduce *uncertainty*.

Model estimation of parameter values will also introduce *uncertainty*.

Introduced level of uncertainty		SCENARIO				
		IDENTICAL	COMPARABLE	DIFFERENT		
SUBSTANCE	IDENTICAL	None	Low	High		
	COMPARABLE	Medium	Medium/High	High/Very high		
	DIFFERENT	High	High/Very high	Very high		

➤ What is considered as "high" uncertainty? A 10-fold deviation? Or a 1000-fold deviation? The level of uncertainty needs to be quantifiable.





Uncertainty when defining the appropriate reference scenario

